RET fusion positive cancer

MONDO:0700216

Neoplasm associated with expression of a RET (REarranged during Transfection) fusion. RET fusion-positive tumors have been identified in a broad range of solid tumor types, including multiple endocrine neoplasia 2 (MEN2), papillary thyroid carcinoma (PTC), non-small cell lung cancer (NSCLC), invasive breast cancers, and pancreatic ductal adenocarcinomas in addition to colorectal adenocarcinoma, melanoma, small cell lung cancer, neuroblastoma, and small intestine neuroendocrine tumors.

Also known as: RET fusion positive neoplasm, RET fusion positive solid tumor, RET fusion positive solid tumour

1450 clinical trials for this condition and its sub-types, 20 tagged with RET fusion positive cancer itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Neoplasm (32585)

Including sub-types (1450) Tagged with RET fusion positive cancer (20)

Trials to join now! 4 Not yet recruiting 3 Not yet finished but already full! 10 Completed 2 Terminated 1

Targeted pill shows promise for rare lung cancer, but trial stopped early

Disease control Stopped early

This phase 3 study tested a new drug called pralsetinib against standard chemotherapy for people with a specific type of advanced lung cancer that has a RET gene fusion. The goal was to see if pralsetinib could better delay cancer growth. The trial was terminated early, so full r…

Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control

Last updated Jun 27, 2026 09:11 UTC

RET fusion positive cancer

Where it sits in the disease tree

Targeted pill shows promise for rare lung cancer, but trial stopped early